



Contact: J. Howison Schroeder
Location: Pittsburgh, PA
Email: hschroeder@neuro-kinetics.com
Tel: +1 (412) 963-6649
Website: www.neuro-kinetics.com



U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
 National Institutes of Health



National Institutes of Health Commercialization Assistance Program
 (NIH-CAP)

Company Profile

Industry Sector: Medical Devices

Company Overview: For over 25 years, Neuro Kinetics, Inc. (NKI) has supplied comprehensive diagnostic tools to audiologists, ENT's, neuro-otologists, neuro-ophthalmologists and neurologists around the globe. Clinicians trust NKI to discover, refine and provide new tests, technologies and protocols to their practice; and to deliver and support the highest quality devices.

NKI's I-Portal® technology sees disease where current tools fail. I-Portal® enables a more precise and sensitive measurement of neuro-physiologic performance by analyzing eye reflexes and responses generated by the brain in response to specific stimuli – the result - a non-invasive, multimodal diagnostic tool that can detect numerous medical conditions at lower cost.

Target Market(s): Ophthalmic diagnostics (retinopathy), and neurology (concussion/mTBI)

Key Value Drivers

Technologies:

- I-Portal® Retinopathy (NIH Phase II) - accurately measures pupillary response as an objective biosensor of retinal function. The device, currently in SBIR funded clinical trials, demonstrated success in quantitatively measuring peripheral retinal dysfunction based on an individual's pupillary response to specific light stimuli.
- NKI Concussion Score™ - soon to be used to detect and monitor concussions/mTBI.

Competitive Advantage: These markets lack cost effective, non-invasive, objective and quantitative diagnostic tools. Existing tests with sufficient sensitivity and specificity are expensive, invasive and cautiously prescribed. Both the I-Portal® Retinopathy and NKI Concussion Score™ fill these important gaps; providing a highly sensitive tool with a small footprint, that can identify abnormal performance earlier and allow intervention to halt the progression of the disease.

I-Portal® Retinopathy Plan & Strategy: Complete two-site clinical trial within 9 months. Attract investor(s)/ strategic partner to support FDA approval and commercial product launch.

Management

- **J. Howison Schroeder** – CEO, M.S., Penn State, Six patents, 10+ years in banking, 15+ years experience with medical startups and mature industrial manufacturing companies.
- **Dr. Alexander Kiderman** – CTO, Ph.D., Academy of Science, Moscow, Russia, 20+ patents, 20+ peer reviewed publications, 30 years combined experience in medical diagnostics, robotics and manufacturing.
- **Vince Kytka** – Director of Operations & Marketing, B.S., Carnegie Mellon University, 10 years experience in marketing, sales and operations, 7 years producing and marketing high technology medical diagnostics.
- **Dr. Robert J. Sclabassi** – Director, MD, Ph.D. Professor (Emeritus) of Neurological Surgery, Neuroscience, Electrical Engineering, Mechanical Engineering, and Biomedical Engineering, University of Pittsburgh.

Product Pipeline

I-Portal® Retinopathy

Month 0: March 2012

Task	3	6	9	12	15	18
Clinical Trials (UCLA, Hopkins)	>	>	>			
Fund Raising	>	>	>	>		
FDA 510K Preparation & Submission			>	>	>	
Reimbursement Strategy			>	>	>	
Final Product Design					>	>
Product Launch						>